Federal Register / Vol. 75, No. 232 / Friday, December 3, 2010 / Notices 75495 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on June 4, 

2010, Clinical Supplies Management, 

Inc., 342 42nd Street South, Fargo, 

North Dakota 58103, made application 

by renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of Sufentanil (9740), a basic 

class of controlled substance listed in 

schedule II. 

The company plans to import the 

listed controlled substance with the sole 

purpose of packaging, labeling, and 

distributing to customers which are 

qualified clinical sites conducting 

clinical trials under the auspices of an 

FDA-approved clinical study. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration, 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43, 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than January 3, 2011. This 

procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: November 18, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30344 Filed 12–2–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on July 28, 

2010, Fisher Clinical Services, Inc., 

7554 Schantz Road, Allentown, 

Pennsylvania 18106, made application 

by renewal to the Drug Enforcement 

Administration (DEA) to be registered as 

an importer of the basic classes of 

controlled substances listed in schedule 

II: 

Drug Schedule 

Noroxymorphone (9668) .............. II 

Tapentadol (9780) ........................ II 

The company plans to import the 

listed substances for analytical research 

and clinical trials. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic classes of controlled 

substances may file comments or 

objections to the issuance of the 

proposed registration, and may, at the 

same time, file a written request for a 

hearing on such application pursuant to 

21 CFR 1301.43, and in such form as 

prescribed by 21 CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

to the Drug Enforcement 

Administration, Office of Diversion 

Control, Federal Register Representative 

(ODL), 8701 Morrissette Drive, 

Springfield, Virginia 22152; and must be 

filed no later than January 3, 2011. 

This procedure is to be conducted 

simultaneously with, and independent 

of, the procedures described in 21 CFR 

1301.34(b), (c), (d), (e), and (f). As noted 

in a previous notice published in the 

Federal Register on September 23, 1975, 

(40 FR 43745–46), all applicants for 

registration to import a basic class of 

any controlled substance in schedule I 

or II are, and will continue to be, 

required to demonstrate to the Deputy 

Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration, that the requirements 

for such registration pursuant to 21 

U.S.C. 958(a); 21 U.S.C. 823(a); and 21 

CFR 1301.34(b), (c), (d), (e), and (f) are 

satisfied. 

Dated: November 18, 2010. 

Joseph T. Rannazzisi, 

Deputy Assistant Administrator, Office of 

Diversion Control, Drug Enforcement 

Administration. 

[FR Doc. 2010–30348 Filed 12–2–10; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

Importer of Controlled Substances; 

Notice of Application 

Pursuant to 21 U.S.C. 958(i), the 

Attorney General shall, prior to issuing 

a registration under this Section to a 

bulk manufacturer of a controlled 

substance in schedule I or II, and prior 

to issuing a regulation under 21 U.S.C. 

952(a)(2) authorizing the importation of 

such a substance, provide 

manufacturers holding registrations for 

the bulk manufacture of the substance 

an opportunity for a hearing. 

Therefore, in accordance with 21 CFR 

1301.34(a), this is notice that on 

September 13, 2010, Chattem 

Chemicals, Inc., 3801 St. Elmo Avenue, 

Building 18, Chattanooga, Tennessee 

37409, made application by letter to the 

Drug Enforcement Administration 

(DEA) to be registered as an importer of 

4-Anilino-N-Phenethyl-4-Piperidine 

(ANPP) (8333), a basic class of 

controlled substance listed in schedule 

II. 

The company plans to import this 

controlled substance in bulk for use in 

the manufacture of another controlled 

substance. 

Any bulk manufacturer who is 

presently, or is applying to be, 

registered with DEA to manufacture 

such basic class of controlled substance 

may file comments or objections to the 

issuance of the proposed registration, 

and may, at the same time, file a written 

request for a hearing on such 

application pursuant to 21 CFR 1301.43, 

and in such form as prescribed by 21 

CFR 1316.47. 

Any such comments or objections 

should be addressed, in quintuplicate, 

mstockstill on DSKH9S0YB1PROD with NOTICES